UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis

Journal of allergy and clinical immunology, 2014-04, Vol.133 (4), p.1032-1040

2014

Volltextzugriff (PDF)

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

The Lancet (British edition), 2008-05, Vol.371 (9625), p.1665-1674

2008

Volltextzugriff (PDF)

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

Journal of the American Academy of Dermatology, 2008, Vol.58 (1), p.106-115

2008

Volltextzugriff (PDF)

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics

Journal of the American Academy of Dermatology, 2019-04, Vol.80 (4), p.1029-1072

2019

Volltextzugriff (PDF)

Guidelines of care for the management of psoriasis and psoriatic arthritis Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics

Journal of the American Academy of Dermatology, 2008-05, Vol.58 (5), p.826-850

2008

Volltextzugriff (PDF)

Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials

JAMA : the journal of the American Medical Association, 2011-08, Vol.306 (8), p.864

2011

Volltextzugriff (PDF)

Guidelines of care for the management of psoriasis and psoriatic arthritis Section 2. Psoriatic arthritis : Overview and guidelines of care for treatment with an emphasis on the biologics

Journal of the American Academy of Dermatology, 2008-05, Vol.58 (5), p.851-864

2008

Volltextzugriff (PDF)

Therapeutic development in psoriasis

Seminars in cutaneous medicine and surgery, 2014-06, Vol.33 (4 Suppl), p.S69-S72

2014

Volltextzugriff (PDF)

Efalizumab: an overview

Journal of the American Academy of Dermatology, 2003-08, Vol.49 (2), p.98-104

Leonardi, Craig L

2003

Volltextzugriff (PDF)

Extended efalizumab therapy improves chronic plaque psoriasis: Results from a randomized phase III trial

Journal of the American Academy of Dermatology, 2005-03, Vol.52 (3), p.425-433

2005

Volltextzugriff (PDF)

Ten years on: the impact of biologics on the practice of dermatology

Dermatologic clinics, 2015-01, Vol.33 (1), p.111-125

2015

Volltextzugriff (PDF)

Efalizumab in the treatment of psoriasis

Dermatologic therapy, 2004-10, Vol.17 (5), p.393-400

Leonardi, Craig L.

2004

Volltextzugriff (PDF)

Impact of adalimumab treatment on patient-reported outcomes: Results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis

The Journal of dermatological treatment, 2007, Vol.18 (6), p.341-350

2007

Volltextzugriff (PDF)

Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis

Journal of the American Academy of Dermatology, 2006-04, Vol.54 (4), p.S164-S170

2006

Volltextzugriff (PDF)

Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis

Journal of drugs in dermatology, 2004-11, Vol.3 (6), p.614

2004

Volltextzugriff (PDF)

A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasis

Dermatology (Basel), 2006-01, Vol.213 (3), p.204-214

2006

Volltextzugriff (PDF)

Clinical efficacy of efalizumab in patients with chronic plaque psoriasis : Results from three randomized placebo-controlled. Phase III trials: Part I

Journal of cutaneous medicine and surgery, 2005-12, Vol.9 (6), p.303-312

2005

Volltextzugriff (PDF)

A Human Interleukin-12/23 Monoclonal Antibody for the Treatment of Psoriasis

The New England journal of medicine, 2007-02, Vol.356 (6), p.580-592

2007

Volltextzugriff (PDF)

Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis

The New England journal of medicine, 2012-03, Vol.366 (13), p.1190-1199

2012

Volltextzugriff (PDF)

Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis

The New England journal of medicine, 2012-03, Vol.366 (13), p.1181-1189

2012

Volltextzugriff (PDF)

Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): Results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials

Journal of the American Academy of Dermatology, 2012-05, Vol.66 (5), p.731-741

2012

Volltextzugriff (PDF)

Pharmacokinetics and Pharmacodynamics of Multiple Weekly Subcutaneous Efalizumab Doses in Patients With Plaque Psoriasis

Journal of clinical pharmacology, 2005-03, Vol.45 (3), p.286-298

2005

Volltextzugriff (PDF)

1 – 22 von 22

Suche als RSS-Feed

Aktive Filter

ThemaAntibodies, Monoclonal - Therapeutic Use

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(22)
Mit Volltextzugriff
(16)

Publikationsform

Artikel
(22)

Sprache

Englisch
(22)

Erscheinungsjahr

n.n

Thema

Humans
(22)
Life Sciences & Biomedicine
(20)
Psoriasis - Drug Therapy
(20)
Science & Technology
(20)
Dermatology
(18)
Adult
(13)
Antibodies, Monoclonal - Adverse Effects
(13)
Biological And Medical Sciences
(13)
Medical Sciences
(13)
Psoriasis
(13)
Psoriasis. Parapsoriasis. Lichen
(13)
Female
(12)
Male
(12)
Middle Aged
(12)
Treatment Outcome
(12)
Double-Blind Method
(9)
Antibodies, Monoclonal - Administration & Dosage
(7)
Severity Of Illness Index
(7)
Aged
(6)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics

Guidelines of care for the management of psoriasis and psoriatic arthritis Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics

Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials

Guidelines of care for the management of psoriasis and psoriatic arthritis Section 2. Psoriatic arthritis : Overview and guidelines of care for treatment with an emphasis on the biologics

Therapeutic development in psoriasis

Efalizumab: an overview

Extended efalizumab therapy improves chronic plaque psoriasis: Results from a randomized phase III trial

Ten years on: the impact of biologics on the practice of dermatology

Efalizumab in the treatment of psoriasis

Impact of adalimumab treatment on patient-reported outcomes: Results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis

Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis

Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis

A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasis

Clinical efficacy of efalizumab in patients with chronic plaque psoriasis : Results from three randomized placebo-controlled. Phase III trials: Part I

A Human Interleukin-12/23 Monoclonal Antibody for the Treatment of Psoriasis

Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis

Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis

Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): Results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials

Pharmacokinetics and Pharmacodynamics of Multiple Weekly Subcutaneous Efalizumab Doses in Patients With Plaque Psoriasis

Aktive Filter

Suchergebnisse filtern